,22 In the FIGHT-202 trial (ClinicalTrials.gov identifier: NCT02924376), the FGFR inhibitor pemigatinib improved median OS from 7.0 to 17.5 months among patients in the FGFR2-altered CCA cohort.25 Here, FGFR2 is linked to cholangiocarcinoma.